E. Kienle

No ORCID on file · 9 papers in corpus · active 1996-2002

Study types

  • article 7
  • other 2

Condition tags

  • endometriosis 9
  • dysmenorrhea 5
  • dyspareunia 4
  • chronic_pelvic_pain 3
  • infertility 2
article 2002
GnRH-agonist leuprorelin acetate versus the gestagen lynestrenol in the treatment of endometriosis
·doi:10.1016/s0015-0282(02)04103-1
article 2001
Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis
·doi:10.1080/713602841

Endometriosis is thought to be an ovarian-dependent benign disease that affects up to 12% of women during their reproductive life. For the past ten years the gonadotropin-releasing hormone (GnRH)-agonists have been proved effective and safe…

article 2001
Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology ·doi:10.1080/gye.15.3.202.209

Endometriosis is thought to be an ovarian-dependent benign disease that affects up to 12% of women during their reproductive life. For the past ten years the gonadotropin-releasing hormone (GnRH)-agonists have been proved effective and safe…

article 2000
Comparison of leprorelin vs. lynestrenol in patients with endometriosis
·doi:10.1016/s0020-7292(00)80617-7
other 2000
Early treatment of endometriosis with GnRH-agonists: impact on time to recurrence
European journal of obstetrics, gynecology, and reproductive biology ·doi:10.1016/s0301-2115(00)00244-x

In a study, 52 patients with histologically confirmed endometriosis underwent a "three-step" therapy. The follow-up period was up to 60 months (median 33.5 months). If r-AFS-score was posttherapeutically 0, recurrence occurred latest after …

article 1999
Effects of Add-Back Therapy on Bone Mineral Density and Pyridinium Crosslinks in Patients with Endometriosis Treated with Gonadotropin-Releasing Hormone Agonists
Gynecologic and obstetric investigation ·doi:10.1159/000010059

Treatment of endometriosis with gonadotropin-releasing hormone agonists (GnRHa) is limited to 6 months because of possible adverse effects on bone metabolism. We designed a randomized, double-blind, placebo-controlled, prospective study of …

article 1998
Steroidal ‘Add-Back’ Therapy in Patients Treated with GnRH Agonists
Gynecologic and obstetric investigation ·doi:10.1159/000052848

GnRH analogues (GnRH-a) are well established in the treatment of endometriosis. However, due to hypooestrogenic effects, treatment is limited to 6 months. The aim of this randomized, double-blind, comparative study was to evaluate whether s…

other 1998
[What is the value of combined surgical-hormonal therapy of endometriosis management?]
Zentralblatt fur Gynakologie

Medical oestrogen suppressive therapy has to be considered as an important principle in the management of endometriosis. In the last years GnRHa became the "gold standard" as pre or postoperative measures before/after surgical intervention.…

article 1996
[Results of long-term follow-up in treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enantone-Gyn monthly depot)].
Zentralblatt fur Gynakologie

In a previous study 198 patients with histologically confirmed endometriosis underwent a "three-step" therapy, where surgical removal of endometriosis implants was followed by a 6 months treatment with 3.75 mg leuprorelinacetate depot as mo…